随着FRUZAQLA®获得首个欧洲退款批准,HUTCHMED从Takeda获得了1000万美元的收入. HUTCHMED earns $10M from Takeda as FRUZAQLA® gains first European reimbursement approval.

在FRUZAQLA(fruquinitinib)首次在欧洲获得偿还许可后,Takeda将支付一笔1 000万美元的里程碑式付款。 HUTCHMED will receive a $10 million milestone payment from Takeda after FRUZAQLA® (fruquintinib) received its first reimbursement approval in Europe. 这一里程碑标志着该药物在欧洲市场上的商业成功。 This milestone marks the drug's commercial success in the European market.